Get the Weekly Intelligence Brief — top committee picks every Sunday.
ADPT · NASDAQ · STOCK

Adaptive Biotechnologies (ADPT) Stock Analysis

Healthcare Updated October 14, 2026
$25.49
52W $12.00 – $30.74
53/100
$4.05B
-62.1
2.10
AI Committee Verdict
Watch
53/100
Conviction: Contested · 33% agreement · 6 analysts
-7.3%
Contested

Is ADPT Bullish or Bearish?

Mixed. Innellis AI committee rates Adaptive Biotechnologies Corporation (ADPT) Watch with a composite score of 53/100 , based on 6 analysts with 33% agreement. Last updated October 14, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +6.81 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -13.19 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 50.1% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 11.3x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Revenue growing 50.1% YoY -- genuine top-line momentum — Growth
  • 4 consecutive earnings beats -- consistent execution — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • Price-to-book of 11.3x prices in significant intangible value — Value
  • ROE of only -32.6% -- cheap may mean cheap for a reason — Value
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 19.1% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 14, 2026
Overall Committee Score
53/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 81%
of 192 Healthcare peers
Value Analyst bearish
30 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− Price-to-book of 11.3x prices in significant intangible value
Growth Analyst bullish
83 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 50.1% YoY -- genuine top-line momentum
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 19.1% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bearish
35 / 100 · Low confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− 2 existing position pair(s) are highly correlated already
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 55.7 to 53.2.

Analyst-level changes:
  • Macro Analyst: score 80->65 (-15).
  • Portfolio Manager: score 30->35 (+5).
  • Risk Analyst: +1 bearish signal(s).

Comparing 2026-10-13 to 2026-10-14 (1 day apart).

Technical Analysis

RSI (14)
38.0
Neutral
MACD Histogram
-0.469
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.13
Inside Bands
Price vs Moving Averages
EMA 9
$26.41 Below
EMA 21
$26.80 Below
EMA 50
$25.74 Below
EMA 200
$20.34 Above

Fundamental Analysis

Valuation
67
Growth
94
Profitability
25
Financial Health
50
Cash Flow
15
Valuation
P/E Ratio -62.1×
P/B Ratio 27.90×
PEG Ratio -1.23
Dividend Yield 0.00%
52W High $30.74
52W Low $12.00
Quality & Growth
ROE -2719.4%
ROA -1160.4%
Gross Margin 7543.6%
Operating Margin -1215.9%
Revenue Growth YoY —
Debt / Equity 2.87
AI Fundamental Assessment
P/E ratio of -62.1 (inexpensive relative to a 15-40x range); Price-to-book of 27.9x; PEG ratio of -1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -27.2%; Return on assets of -11.6%; Net margin of -20.7%; Gross margin of 75.4%; Current ratio of 4.79 (healthy short-term liquidity); Debt-to-equity of 2.87; Free cash flow per share is negative (-0.15); Most recent quarter beat estimates by 26.7%; 4 consecutive earnings beats; EPS growth accelerating (-33.3% -> +16.7% QoQ); Analyst estimates rising over recent quarters
Get the Full ADPT Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime